Electronic supplementary information

Robust silver-mediated imidazolo-dC base pairs in metal DNA: dinuclear silver bridges with exceptional stability in double helices with parallel and antiparallel strand orientation

Sunit Kumar Jana,^a Xiurong Guo,^{a,c} Hui Mei,^a and Frank Seela*^{a,b}

^aLaboratory of Bioorganic Chemistry and Chemical Biology, Center for Nanotechnology, Heisenbergstraße 11, 48149 Münster, Germany

^b Laboratorium für Organische und Bioorganische Chemie, Institut für Chemie neuer Materialien,

Universität Osnabrück, Barbarastraße 7, 49069 Osnabrück, Germany

^cInstitute for Nanobiomedical Technology and Membrane Biology, West China Medicinal School, No.

1 Keyuan 4th Road, Gaopengdadao, Chengdu 610041, P.R. China

Corresponding author: Prof. Dr. Frank Seela

Phone: +49 (0) 251 53406 500; Fax: +49 (0) 251 53406 857

E-mail: Frank.Seela@uni-osnabrueck.de

Homepage: <u>www.seela.net</u>

Contents

General methods and materials	S3
Synthesis, purification, and characterization of oligonucleotides	S3
Experimental procedures	S5
Table S1. ¹³ C NMR chemical shifts of compounds 1 , 3 , 5 and 7	S10
Table S2. ¹ H- ¹³ C coupling constants.	S10
Fig. S1. Structures of iG_d and ${}^{5me}iC_d$ phosphoramidites	S10
Quantum yield determination	S11
Table S3. Photophysical properties of fluorescent nucleosides	S11
Fig. S2-S5. pK_a determination by fluorescence and UV	S12
Table S4. Mass spectrometric data of oligonucleotides	
Fig. S6. HPLC profiles of oligonucleotides	\$16
Fig. S7-S19. Stoichiometric titrations	S17
Table S5. Additional T _m table	
Table S6. $T_{\rm m}$ values and thermodynamic data of duplexes with parallel and	antiparallel
chain orientation	
Fig. S20. Melting profiles of oligonucleotides	S31
References	S34
Fig. S21-S40. NMR spectra of compounds 1 , 3 , 5 , 6 , 7 and 8	

General methods and materials.

All chemicals and solvents were of laboratory grade as obtained from commercial suppliers and were used without further purification. Thin-layer chromatography (TLC) was performed on TLC aluminium sheets covered with silica gel 60 F254. Flash column chromatography (FC): silica gel 60 at 0.4 bar. UV-spectra: U-3200 UV-vis spectrometer. ¹H, ¹³C and ³¹P NMR spectra were measured at 300.15 MHz for 1 H, 75.48 MHz for 13 C, and 121.52 MHz for 31 P. δ values in ppm rel. to Me₄Si as internal standard (1 H and 13 C) or external 85% H₃PO₄ (31 P). The J values are given in Hz. For NMR spectra measured in DMSO- d_6 , the chemical shift of the solvent peak was set to 2.50 ppm for ¹H-NMR and 39.50 ppm for ¹³C-NMR. DEPT-135 and ¹H-¹³C gated-decoupled spectra were used for the assignment of the ¹³C signals (Table S1). For ¹H-¹³C coupling constants see Table S2. Reversed-phase HPLC was carried out on a 4×250 mm RP-18 (10 µm) LiChrospher 100 column with a HPLC pump connected with a variable wavelength monitor, a controller and an integrator. The molecular masses of the oligonucleotides were determined by MALDI-TOF mass spectrometry in the linear positive mode with 3-hydroxypicolinic acid (3-HPA) as a matrix. The thermal melting curves were measured with a UV/Vis spectrophotometer equipped with a thermoelectrical controller. The temperature was measured continuously in the reference cell with a Pt-100 resistor with a heating rate of 1°C min⁻¹. The calculation of thermodynamic data was performed with the program MeltWin¹ (version 3.0) using curve fitting of the melting profiles according to a twostate model.

Synthesis, purification, and characterization of oligonucleotides.

The oligonucleotide syntheses were performed on an ABI 392-08 synthesizer at 1 μ mol scale (trityl-on mode) employing the standard phosphoramidites and the modified building blocks **6** and **8** following the synthesis protocol for 3'-cyanoethyl phosphoramidites. The average coupling yield was always higher than 95%. After cleavage from the solid support, the

oligonucleotides were deprotected in 28% aq. NH₃ for 2 days at room temperature. The DMTcontaining oligonucleotides were purified by reversed-phase HPLC (RP-18) with the following solvent gradient system: A: 0.1 M (Et₃NH)OAc (pH 7.0)/MeCN 95:5; B: MeCN; gradient I: 0-3 min 10-15% B in A, 3-15 min 15-50% B in A, 15-20 min 50-10% B in A, flow rate 0.8 mL min⁻¹. Then, the mixture was evaporated to dryness, and the residue was treated with 2.5% Cl₂CHCOOH/CH₂Cl₂ for 3 min at 0 °C to remove the 4,4'-dimethoxytrityl residues. The detritylated oligomers were purified by reversed-phase HPLC with the gradient II: 0-20 min 0-20% B in A, 20-25 min 20% B in A, 25-30 min 20-0% B in A, flow rate 0.8 mL min⁻¹. The oligomers were desalted on a short column (RP-18, silica gel) using H₂O for elution of the salt, while the oligomers were eluted with MeOH/H₂O (3:2). The purity of the oligonucleotides was confirmed by MALDI-TOF mass spectra (Table S4) and HPLC (RP-18) profiles (Figure S6). The oligonucleotides were lyophilized on a Speed Vac evaporator to yield colourless solids which were stored frozen at -24°C. The extinction coefficients ε_{260} (H₂O) of the nucleosides are: dA 15400, dG 11700, dT 8800, dC 7300, **1** 1400 (MeOH), **2** 22900 (MeOH) and 3 12400 (MeOH). The extinction coefficients of the oligonucleotides were calculated from the sum of the extinction coefficients of the nucleoside constituents.

Experimental procedures.

1-(2-Deoxy-β-D-erythro-pentofuranosyl)-1*H*-purin-2(9*H*)-one (1).



Compound 4^2 (500 mg, 2.06 mmol) in diethoxymethyl acetate (5 mL) was heated at 100 °C for 3 h. Then, water (3 mL) was added and evaporated under high vacuum. The residue was purified by FC (silica gel, column 15 × 3 cm, CH₂Cl₂/MeOH, 100:15) to yield colourless solid **1** (150 mg, 0.60 mmol, 29%). TLC (silica gel, CH₂Cl₂/MeOH, 9:1): R_f 0.18. λ_{max} (MeOH)/nm 217 (ϵ /dm³ mol⁻¹ cm⁻¹ 16900), 324 (3700).¹H NMR (300 MHz, DMSO- d_6): δ 1.99-2.07 (m, 1H, 2'-H), 2.31-2.39 (m, 1H, 2'-H), 3.59-3.72 (m, 2H, 2 x 5'-H), 3.88-3.89 (m, 1H, 4'-H), 4.23 (br, 1H, 3'-H), 5.23-5.26 (m, 2H, 3'-OH, 5'-OH), 6.18 (t, *J* = 6.3 Hz, 1H, 1'-H), 8.18 (s, 1H, H-8), 8.95 (s, 1H, H-6), 12.61 (br, 1H, NH). ESI-TOF: *m/z* calcd. for C₁₀H₁₂N₄O₄ [M + Na]⁺ 275.0751, found 275.0750.

1-[2-Deoxy-5-*O*-(4,4'-dimethoxytriphenylmethyl)-β-D-*erythro*-pentofuranosyl]-1*H*-purin-2(9*H*)-one (5).



Compound **1** (300 mg, 1.2 mmol) was co-evaporated with pyridine (2×10 mL) before dissolving in pyridine (15 mL). Then, 4,4'-dimethoxytrityl chloride (950 mg, 2.88 mmol) was

added in three portions, and the reaction mixture was stirred at room temperature for 16 h. Finally, MeOH (2 mL) was added, and the mixture was stirred for another 20 min. The reaction mixture was diluted with CH₂Cl₂ (2 × 20 mL) and extracted with 5% aqueous NaHCO₃ solution (50 mL). The organic layer was dried over Na₂SO₄, and then concentrated. Purification by FC (silica gel, column 15 × 3 cm, CH₂Cl₂/acetone, 80:20) gave **5** as a light yellow solid (450 mg, 0.53 mmol, 44% yield). TLC (silica gel, CH₂Cl₂/acetone, 4:1): R_f 0.40. λ_{max} (MeOH)/nm 225 (ϵ /dm³ mol⁻¹ cm⁻¹ 56100), 324 (7700). ¹H NMR (300 MHz, DMSO- d_6): δ 2.05-2.12 (m, 1H, 2'-H_α), 2.31-2.37 (m, 1H, 2'-H_β), 3.17-3.29 (m, 2H, 2 x 5'-H), 3.65-3.79 (m, 12H, 4 x OCH₃), 4.00-4.01 (m, 1H, 4'-H), 4.20-4.22 (m, 1H, 3'-H), 5.31 (d, *J* = 4.5 Hz, 1H, 3'-OH), 6.08 (t, *J* = 6.0 Hz, 1H, 1'-H), 6.81-6.90 (m, 8H, DMTr-H), 7.04-7.08 (m, 4H, DMTr-H), 7.11-7.18 (m, 4H, DMTr-H), 7.21-7.31 (m, 8H, DMTr-H), 7.33-7.40 (m, 2H, DMTr-H), 7.87 (s, 1H, 8-H), 8.59 (s, 1H, 6-H). ESI-TOF: *m*/*z* calcd. for C₅₂H₄₈N₄O₈ [M + Na]⁺ 879.3364, found 879.3371.

1-[2-Deoxy-5-*O*-(4,4'-dimethoxytriphenylmethyl)-β-D-*erythro*-pentofuranosyl]-1*H*-purin-2(9*H*)-one 3'-(2-cyanoethyl)-*N*,*N*'-diisopropyl phosphoramidite (6).



A stirred solution of **5** (600 mg, 0.70 mmol) in anhydrous CH_2Cl_2 (12 mL) was treated with $(i\text{-}Pr)_2NEt$ (210 µL, 1.20 mmol) followed by 2-cyanoethyl-*N*,*N*-diisopropylphosphoramidochloridite (210 µL, 0.94 mmol). After stirring for 20 min at room temperature, the solution was diluted with CH_2Cl_2 (40 mL) and extracted with 5% aq. NaHCO₃ solution (30 mL). The organic layer was dried over Na₂SO₄ and evaporated. The residue was purified by FC (silica gel, column 10 x 2 cm, CH₂Cl₂/acetone, 8:1) giving **6** (215 mg, 0.20 mmol, 29% yield) as a light yellow foam. TLC (silica gel, CH₂Cl₂/acetone, 5:1): $R_{\rm f}$ 0.50. ³¹P NMR (121 MHz, CDCl₃): δ 148.55, 148.97. ESI-TOF: *m/z* calcd. for C₆₁H₆₅N₆NaO₉P [M + Na]⁺ 1079.4443, found 1079.4415.

1-(2-Deoxy-β-D-*erythro*-pentofuranosyl)-8-furyl-1*H*-purin-2(9*H*)-one (3).



Furfural (108 μL, 1.3 mmol), and ceric (IV) ammonium nitrate (110 mg, 0.2 mmol) were added to a solution of 5-amino-dC 4^2 (242 mg, 1.0 mmol) in DMF (10 mL). The solution was heated to 55 °C and stirred for 24 h. The solvent was evaporated to dryness, and the residue was purified by FC (silica gel, column 15 × 3 cm, CH₂Cl₂/MeOH, 10:1) to yield light yellow solid **3** (180 mg, 0.57 mmol, 57% yield). TLC (silica gel, CH₂Cl₂/MeOH, 5:1): R_f 0.43. λ_{max} (MeOH)/nm 274 (ϵ /dm³ mol⁻¹ cm⁻¹ 17200), 346 (14800). ¹H NMR (300 MHz, DMSO- d_6): δ 2.03-2.11 (m, 1H, 2'-H_α), 2.32-2.40 (m, 1H, 2'-H_β), 3.60-3.74 (m, 2H, 2 x 5'-H), 3.88-3.90 (m, 1H, 4'-H), 4.24-4.25 (m, 1H, 3'-H), 5.25-5.27 (m, 2H, 3'-OH, 5'-OH), 6.21 (t, *J* = 6.1 Hz, 1H, 1'-H), 6.72-6.74 (m, 1H, furyl), 7.26-7.27 (m, 1H, furyl), 7.93-7.97 (m, 1H, furyl), 8.90 (s, 1H, 6-H), 13.10 (s, 1H, NH). ESI-TOF: *m*/*z* calcd. for C₁₄H₁₄N₄O₅ [M + Na]⁺ 341.0856, found 341.0867.

1-[2-Deoxy-5-*O*-(4,4'-dimethoxytriphenylmethyl)-β-D-*erythro*-pentofuranosyl]-8-furyl-1*H*-purin-2(9*H*)-one (7).



Compound **3** (637 mg, 2.0 mmol) was co-evaporated with pyridine (2 × 10 mL) before dissolving in pyridine (10 mL). Then, 4,4'-dimethoxytrityl chloride (879 mg, 2.60 mmol) was added in three portions, and the reaction mixture was stirred at room temperature for 16 h. Finally, MeOH (2 mL) was added, and the mixture was stirred for another 20 min. The reaction mixture was diluted with CH₂Cl₂ (2 × 20 mL) and extracted with 5% aqueous NaHCO₃ solution (50 mL). The organic layer was dried over Na₂SO₄, and then concentrated. Purification by FC (silica gel, column 15 × 3 cm, CH₂Cl₂/MeOH, 98:2) gave **7** as a light yellow solid (757 mg, 0.94 mmol, 47% yield). TLC (silica gel, CH₂Cl₂/MeOH, 10:1): *R*_f 0.48. λ_{max} (MeOH)/nm 274 (ϵ /dm³ mol⁻¹ cm⁻¹ 19000), 252 (14400). ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.12-2.21 (m, 1H, 2'-H_α), 2.36-2.44 (m, 1H, 2'-H_β), 3.21–3.30 (m, 2H, 2 x 5'-H), 3.71 (2s, 6H, 2 x OCH₃), 4.02-4.03 (m, 1H, 4'-H), 4.18-4.22 (m, 1H, 3'-H), 5.34 (d, *J* = 4.2 Hz, 1H, 3'-OH), 6.24 (t, *J* = 6.3 Hz, 1H, 1'-H), 6.74-6.76 (m, 1H, furyl), 6.89-6.92 (m, 4H, 3 x DMTr-H, 1 x 1H, furyl), 7.19-7.42 (m, 10H, DMTr-H), 7.98-7.99 (m, 1H, furyl), 8.53 (s, 1H, 6-H), 13.13 (s, 1H, 7-NH). ESI-TOF: *m*/*z* calcd. for C₃₅H₃₂N₄NaO₇ [M + Na]⁺ 643.2163, found 643.2166.

S8

1-[2-Deoxy-5-*O*-(4,4'-dimethoxytriphenylmethyl)-β-D-*erythro*-pentofuranosyl]-8-furyl-1*H*-purin-2(9*H*)-one 3'-(2-cyanoethyl)-*N*,*N*'-diisopropyl phosphoramidite (8).



A stirred solution of **7** (150 mg, 0.44 mmol) in anhydrous CH₂Cl₂ (10 mL) was treated with $(i-Pr)_2NEt$ (75 µL, 0.42 mmol) followed by 2-cyanoethyl-*N*,*N*-diisopropylphosphoramidochloridite (67 µL, 0.3 mmol). After stirring for 10 min at room temperature, the solution was diluted with CH₂Cl₂ (40 mL) and extracted with 5% aq. NaHCO₃ solution (30 mL). The organic layer was dried over Na₂SO₄ and evaporated. The residue was purified by FC (silica gel, column 10 x 2 cm, CH₂Cl₂/methanol, 10:1) giving **8** (154 mg, 0.19 mmol, 79% yield) as a light yellow foam. TLC (silica gel, CH₂Cl₂/acetone, 1:1): R_f 0.41. ³¹P NMR (121 MHz, CDCl₃): δ 148.76, 149.18. ESI-TOF: *m*/*z* calcd. for C₄₄H₄₉N₆O₈P [M + H]⁺ 821.3422, found 821.3477.

	$C(2)^b$ $C(2)^c$	$C(4)^b$ $C(7a)^c$	$\frac{\mathrm{C(5)}^{b}}{\mathrm{C(4a)}^{c}}$	$C(6)^b$ $C(4)^c$	$C(8)^b$ $C(6)^c$	C(1')	C(2')	C(3')	C(4')	C(5')	OMe	Furan
1	153.8	160.1	122.7	135.1	146.6	87.0	41.2	69.2	87.7	60.4		
3	153.1	160.9	124.4	133.7	144.3	87.0	41.2	69.2	87.7	60.4		112.3, 112.6, 113.0, 145.8
5	152.5	159.3	124.4	135.4	147.4	87.3	40.9	70.0	86.1	63.3	54.8, 54.9	
7	158.0 ^d	161.2	126.7 ^d	133.3	144.8	87.2	40.3	69.9	86.1	63.6	54.9	112.5, 113.2, 113.3, 146.1

Table S1. ¹³C NMR chemical shifts of compounds **1**, **3**, **5** and **7**. ^{*a*}

^{*a*} Measured in DMSO-*d*₆ at 298 K. ^{*b*} Purine numbering. ^{*c*} Systematic numbering. ^{*d*} Tentative.

Table S2. Selected ¹H-¹³C coupling constants (Hz) of nucleosides 1, 3, 5 and 7.^{*a*}

	1	3	5	7
${}^{1}J(C6, H-C6)$	185.5	185.2	184.3	183.0
¹ <i>J</i> (C1', H-C1')	175.5	173.0	175.2	174.8
¹ <i>J</i> (C3', H-C3')	147.9	147.4	150.2	150.6
¹ <i>J</i> (C4', H-C4')	147.3	147.2	148.4	149.2
¹ <i>J</i> (C5', H-C5')	141.6	139.5	140.2	141.0

^{*a* 1}H-¹³C gated-decoupled NMR spectra were measured in DMSO- d_6 at 298 K.



Fig. S1. Structures of phosphoramidites iG_d (9) and ${}^{5me}iC_d$ (10).

Quantum yield determination.

The fluorescence quantum yield (Φ_f) was determined by a relative method with quinine sulfate in 0.1 M H₂SO₄ ($\Phi_f = 0.54$) as a reference standard.³ The quantum yield of the unknown $\Phi_{(x)}$ can be calculated by the following equation:

 $\Phi_{(x)} = \Phi_{(ST)}(A_{ST}/A_X)(F_X/F_{ST})(\eta^2_X/\eta^2_{ST})$

Where $\Phi_{(ST)}$ is the quantum yield of the standard, A is the absorbance at the excitation wavelength, F is the integrated area in the emission curve, the subscripts X and ST refer to unknown and standard and η is the refractive index of solvent.

 Table S3. Photophysical properties of fluorescent nucleosides.

Compounds	λ _{max} [nm]	ϵ_{max} [mol ⁻¹ dm ³ cm ⁻¹]	Ex _{max} [nm]	Em _{max} [nm]	Quantum yield $(\Phi)^a$
1	324	3700	324	388	0.03 ^b
2	344	13500	342	398	0.33 ^{<i>b</i>}
3	346	14800	350	399	0.39 ^{<i>b</i>}

^{*a*} Quantum yields were determined using quinine sulfate in 0.1 M H₂SO₄ as standard with $\Phi = 0.54$.

^{*b*} Determined in methanol.



pK_a Determination by fluorescence and UV.

Nucleosides 1 or 3 were dissolved in 0.1 M sodium phosphate buffer, pH 4.5. NaOH solution (4 M) and concentrated phosphorus acid was used to adjust the pH value of the buffer. At defined pH values, the fluorescence of nucleoside 1 or 3 was measured. At each pH value emission spectra were measured with excitation at 324 nm for 1 and 350 nm for 3. The fluorescence intensity at 388 nm for 1 and 400 nm for 3 were recorded to determine the pK_a values of nucleosides 1 and 2. For comparison, the pK_a values of nucleosides 1 and 2 were also determined UV-spectrophotometrically.



Fig. S2 (a) pH Dependent fluorescence spectra of nucleoside **1**. The excitation wavelength was set to 324 nm. (b) Fluorescence intensity (a.u.) *vs* pH-value and its first derivative using data from (a).



Fig. S3 (a) pH Dependent fluorescence spectra of nucleoside **3**. The excitation wavelength was set to 350 nm. (b) Fluorescence intensity (a.u.) *vs* pH-value and its first derivative using data from (a).



Fig. S4 (a) and (b) UV spectroscopic change of nucleoside **1** at various pH values and (c) absorbance at 276 nm *vs* pH-value and its first derivative using data from (b).



Fig. S5 (a) and (b) UV spectroscopic change of nucleoside **3** at various pH values and (c) absorbance at 300 nm *vs* pH-value and its first derivative using data from (b).

Table S4. Molecular masses of oligonucleotides measured by MALDI-TOF mass

 spectrometry.^a

Oligonucleatides	Molecular Weight [u]			
Oligonucleotides	$[\mathbf{M}+\mathbf{H}]^{+}$ Calc.	[M+H] ⁺ Found		
5'-d(TAG GT1 AAT ACT) ODN-3	3670.4	3671.3		
5'-d(ATiC iCA 1 TTA TiGA) ODN-4	3658.5	3655.6		
5'-d(ATiC iCA 2 TTA TiGA) ODN- 6	3734.5	3731.4		
5'-d(TAG GT3 AAT ACT) ODN-7	3736.5	3734.9		
5'-d(ATiC iCA 3 TTA TiGA) ODN-8	3724.5	3722.7		
5'-d(AGT ATT 1AC CTA) ODN-10	3630.5	3629.0		
5'-d(AGT ATT 3 AC CTA) ODN-12	3696.5	3695.4		
5'-d(TiCA TAA 1TiG iGAT) ODN-14	3684.5	3683.0		
5'-d(TiCA TAA 2TiG iGAT) ODN-15	3760.5	3762.3		
5'-d(TiCA TAA 3 TiG iGAT) ODN- 16	3750.5	3750.8		

 $^{\it a}$ Measured in the linear positive mode. iC corresponds to $^{5me}iC_d.$

HPLC profiles of oligonucleotides determined at 260 nm.

HPLC (RP-18) profiles of single-stranded oligonucleotides determined at 260 nm. For elution the following solvent system was used: 0.1 M (Et₃NH)OAc (pH 7.0) : MeCN (95:5) (A) and MeCN (B). Gradient: 0-20 min 0-20% B in A, 20-25 min 20% B in A, 25-30 min 20-0% B in A, flow rate 0.8 mL min⁻¹.



S16



Fig. S6 HPLC profiles of oligonucleotides. (a) 5'-d(TAG GT1 AAT ACT) ODN-**3**, (b) 5'-d(ATiCiCA1TTATiGA) ODN-**4**, (c) 5'-d(ATiCiCA2TTATiGA) ODN-**6**, (d) 5'-d(TAG GT**3** AAT ACT) ODN-**7**, (e) 5'-d(ATiCiCA**3**TTATiGA) ODN-**8**, (f) 3'-d(ATC CA1 TTA TGA) ODN-**10**, (g) 5'-d(TiCATAA1TiGiGAT) ODN-**14**, (h) 5'-d(TiCATAA2TiGiGAT) ODN-**15**, (i) 3'-d(ATC CA**3** TTA TGA) ODN-**12**, (j) 5'-d(TiCATAA**3**TiGiGAT) ODN-**16**. X-axis refers to time (min), Y-axis refers to UV-absorbance at 260 nm (a.u.).

Stoichiometric titration.

To a solution containing 5 μ M + 5 μ M of the single-stranded oligonucleotides in 1 mL of 100 mM NaOAc, 10 mM Mg(OAc)₂ buffer (pH 7.5) was added 2 μ L of a 1 mM AgNO₃ stock solution in bid. H₂O. Thus, a ratio of the silver/duplex of 0.4:1 was obtained. Then, in a stepwise manner 2 μ L of the AgNO₃ stock solution were added until a final ratio of silver to DNA duplex of 4:1 was reached. After each addition of the stock solution, the mixture was equilibrated for 5 min (at 20 °C). The UV-absorption spectra were recorded in the range of 220-450 nm and fluorescence emission spectra were recorded in the range of 380-600 nm. Titration studies on ps duplexes ODN-**3** • ODN-**4**, ODN-**5** • ODN-**6**, ODN-**7** • ODN-**8**, ODN-**10** • ODN-**11** • ODN-**15**, ODN-**12** • ODN-**16** and aps duplexes ODN-**3** • ODN-**10**, and ODN-**7** • ODN-**12** were performed according to this procedure. Then, the UV absorbance changes at selected wavelengths were plotted vs the ratio of silver/duplex to establish the stoichiometry.

Titration studies on monomeric nucleosides 1 and 3 (10 μ M) were also performed using the procedure described above.

Stoichiometric titration of nucleosides.



Fig. S7 (a) UV spectrophotometric titration of nucleoside **1** (10 μ M) with increasing concentration of Ag⁺ ions (0–4.0 equiv) in buffer solution (100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5) containing 0.5% DMSO at 20 °C. (b) Graph of ratio of equivalents of silver ions/nucleoside **1** versus changes in absorbance at different wavelengths from (a).



Fig. S8 (a) Fluorescence spectra of nucleoside **1** with increasing concentration of Ag^+ ions (0–4.0 equiv) in buffer solution (100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5) containing 0.5% DMSO at 20 °C. b) Graph of ratio of equivalents of silver ions/nucleoside **1** versus changes in fluorescence intensity (a. u.) at 400 nm. The excitation wavelength was set to 324 nm.



Fig. S9 (a) UV spectrophotometric titration of nucleoside **3** (10 μ M) with increasing concentration of Ag⁺ ions (0-4.0 equiv) in buffer solution (100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5) containing 0.5% DMSO at 20 °C. (b) Graph of ratio of equivalents of silver ions/nucleoside **3** versus changes in absorbance at different wavelengths from (a).



Fig. S10 (a) Fluorescence spectra of nucleoside **3** with increasing concentration of Ag^+ ions (0-4.0 equiv) in buffer solution (100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5) containing 0.5% DMSO at 20 °C. b) Graph of ratio of equivalents of silver ions/nucleoside **3** versus changes in fluorescence intensity (a. u.) at 400 nm. The excitation wavelength was set to 350 nm.

Stoichiometric titration of oligonucleotides.



Fig. S11 (a) UV titration of ODN-**1** • ODN-**1a** (5 μ M + 5 μ M) with increasing Ag⁺ concentration in 100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5. (b) Graph of ratio of equivalents of silver ions/duplex versus changes in absorbance at 260 nm.



Fig. S12 (a) UV and (c) fluorescence titration of ODN-**3** • ODN-**4** (5 μ M + 5 μ M) with increasing Ag⁺ concentration in 100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5. (b) and (d) Determination of the silver to duplex ratio at different wavelengths from (a) and (c).



Fig. S13 (a) UV and (c) fluorescence titration of ODN-**5** • ODN-**6** (5 μ M + 5 μ M) with increasing Ag⁺ concentration in 100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5. (b) and (d) Determination of the silver to duplex ratio at different wavelengths from (a) and (c).



Fig. S14 (a) UV and (c) fluorescence titration of ODN-7 • ODN-8 (5 μ M + 5 μ M) with increasing Ag⁺ concentration in 100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5. (b) and (d) Determination of the silver to duplex ratio at different wavelengths from (a) and (c).



Fig. S15 (a) Fluorescence titration of ODN-10 • ODN-14 (5 μ M + 5 μ M) with increasing Ag⁺ concentration in 100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5. (b) Determination of the silver to duplex ratio at different wavelengths from (a).



Fig. S16 (a) UV and (c) fluorescence titration of ODN-**11** • ODN-**15** (5 μ M + 5 μ M) with increasing Ag⁺ concentration in 100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5. (b) and (d) Determination of the silver to duplex ratio at different wavelengths from (a) and (c).



Fig. S17 (a) UV and (c) fluorescence titration of ODN-**12** • ODN-**16** (5 μ M + 5 μ M) with increasing Ag⁺ concentration in 100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5. (b) and (d) Determination of the silver to duplex ratio at different wavelengths from (a) and (c).



Fig. S18 (a) Fluorescence titration of ODN-**3** • ODN-**10** (5 μ M + 5 μ M) with increasing Ag⁺ concentration in 100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5. (b) Determination of the silver to duplex ratio at different wavelengths from (a).



Fig. S19 (a) UV and (c) fluorescence titration of ODN-7 • ODN-12 (5 μ M + 5 μ M) with increasing Ag⁺ concentration in 100 mM NaOAc, 10 mM Mg(OAc)₂, pH = 7.5. (b) and (d) Determination of the silver to duplex ratio at different wavelengths from (a) and (c).

Duplexes		T _m [°C] with <i>n</i> equiv	$\Delta T_{\rm m}$ [°C] relative			
Duplexes	n = 0	<i>n</i> = 1	<i>n</i> = 2	to mismatch ^b			
	ps du	plex DNA ((pattern 1)				
5'-d(TAG GT1 AAT ACT) 5'-d(ATiC iCA1 TTA TiGA)	ODN- 3 ODN- 4	n.d.	n.d./53.0 ^c	53.0	n.d.		
5'-d(TAG GT2 AAT ACT) 5'-d(ATiC iCA2 TTATiGA)	ODN- 5 ODN- 6	27.0	n.d./54.0 ^c	54.0	+27.0		
5'-d(TAG GT 3 AAT ACT) 5'-d(ATiC iCA 3 TTA TiGA)	ODN- 7 ODN- 8	25.0	20.0/63.0 ^c	63.0	+38.0		
ps duplex DNA (pattern 2)							
5'-d(AGT ATT 1AC CTA) 5'-d(TiCA TAA 1TiG iGAT)	ODN- 10 ODN- 14	n.d.	n.d./53.0 ^c	53.0	n.d.		
5'-d(AGT ATT 2 AC CTA) 5'-d(TiCA TAA 2 TiG iGAT)	ODN- 11 ODN- 15	n.d.	n.d./53.0 ^c	53.0	n.d.		
5'-d(AGT ATT 3 AC CTA) 5'-d(TiCA TAA 3 TiG iGAT)	ODN- 12 ODN- 16	n.d.	n.d./59.0 ^c	59.0	n.d.		
		aps duplex	DNA				
5'-d(TAG GTC AAT ACT) 3'-d(ATC CAG TTA TGA)	ODN-1 ODN-9	42.5	43.0	41.5	-1.0		
5'-d(TAG GT1 AAT ACT) 3'-d(ATC CA1 TTA TGA)	ODN- 3 ODN- 10	23.0	27.0/66.0 ^c	65.0	+42.0		
5'-d(TAG GT 2 AAT ACT) 3'-d(ATC CA 2 TTA TGA)	ODN- 5 ODN- 11	32.5	31.5/70.0 ^c	71.0	+38.5		
5'-d(TAG GT 3 AAT ACT) 3'-d(ATC CA 3 TTA TGA)	ODN- 7 ODN- 12	26.0	26.0/74.0 ^c	74.5	+48.5		

Table S5. $T_{\rm m}$ values of DNA duplexes containing ImidC derivatives (1-3) in the presence or absence of silver ions.^{*a*}

^{*a*} Measured at 260 nm with 5 μ M + 5 μ M single-strand concentration at a heating rate of 1.0 °C/min in 100 mM NaOAc pH 7.3 in the presence of various concentrations of AgNO₃ (0-2.0 equivalents). Melting was performed in the range of 15-90°C. T_m values were calculated from the heating curves. $^{$ *b* $}\Delta T_m = T_m$ after the addition of 2.0 equivalents AgNO₃ – T_m before the addition of AgNO₃. ^{*c*} Biphasic melting. n.d. not determined.

Duplexes		eq. of	$T_{\rm m}$	-ΔΗ ^c	- ΔS^{c}	$-\Delta G^{c}$			
		Ag^+	[°C]	[kcal/mol]	[cal/K/mol]	[kcal/mol]			
ps duplex DNA (pattern I)									
5'-d(TAG GTC AAT ACT)	ODN-1	0	34.5	60.5	170.9	7.5			
5'-d(ATiCiCA iG TTATiGA)	ODN-2	2	33.5	60.2	169.5	7.3			
5'-d(TAG GT1 AAT ACT)	ODN-3	0	28.0	57.4	165.0	6.2			
5'-d(ATiCiCA1 TTATiGA)	ODN-4	2	55.0	48.5	122.6	10.5			
5'-d(TAG GT2 AAT ACT)	ODN-5	0	31.0	64.6	186.9	6.6			
5'-d(ATiCiCA2 TTATiGA)	ODN-6	2	58.0	64.1	167.7	12.1			
5'-d(TAG GT3 AAT ACT)	ODN-7	0	29.0	58.5	167.8	6.5			
5'-d(ATiCiCA3 TTATiGA)	ODN-8	2	67.0	53.8	132.5	12.7			
	ps duplex D	NA (patt	ern II)						
5'-d(AGT ATT GAC CTA)	ODN-9	0	42.0	88.9	256.2	9.4			
5'-d(TiCA TAA iC TiG iGAT)) ODN-13	2	42.0	88.9	256.7	9.3			
5'-d(AGT ATT 1AC CTA)	ODN-10	0	28.0	63.0	183.6	6.1			
5'-d(TiCA TAA 1TiG iGAT)	ODN-14	2	57.0	62.9	164.6	11.8			
5'-d(AGT ATT 2AC CTA)	ODN-11	0	32.0	67.1	194.5	6.7			
5'-d(TiCA TAA 2 TiG iGAT)	ODN-15	2	61.0	64.5	167.2	12.6			
5'-d(AGT ATT 3 AC CTA)	ODN-12	0	28.0	62.4	181.3	6.2			
5'-d(TiCA TAA 3 TiG iGAT)	ODN-16	2	66.0	58.6	147.4	12.9			
		aps duple	ex DNA						
5'-d(TAGGTCAATACT)	ODN-1	0	46.5	67.5	185.4	10.0			
3'-d(ATCCAGTTATGA)	ODN-9	2	46.5	67.5	185.4	10.0			
5'-d(TAGGT1AATACT)	ODN-3	0	32.0	50.9	141.3	7.1			
3'-d(ATCCA1TTATGA)	ODN-10	2	71.0	_ d	d	- ^d			
5'-d(TAGGT 3 AATACT)	ODN-7	0	30.0	62.5	180.1	6.6			
3'-d(ATCCA 3 TTATGA)	ODN-12	2	78.0	_ <i>d</i>	_ <i>d</i>	_ d			

Table S6. $T_{\rm m}$ values and thermodynamic data of duplexes with parallel and antiparallel chain orientation^{*a,b*}

^{*a*} Measured at 260 nm with 5 μ M + 5 μ M single-strand concentration at a heating rate of 1.0 °C/min in 100 mM NaOAc, 10 mM Mg(OAc)₂ pH 7.5 in the presence of various concentrations of AgNO₃ (0-2.0 equivalents). ^{*b*} See references 4a,b. ^{*c*} $T_{\rm m}$ values and thermodynamic data were determined with the program MeltWin 3.0 and are with 10% deviation. ^{*d*} $T_{\rm m}$ values are too high to get reliable thermodynamic data.

Melting profiles of oligonucleotides.



(e)

(f)



Fig. S20 Thermal denaturation curves of ps and aps duplexes with increasing concentration of Ag^+ ions. The experiments were performed with 5 μ M duplex concentration in 100 mM NaOAc, 10 mM Mg(OAc)₂ buffer (pH 7.5) at 260 nm. (a) ODN-**3** • ODN-**4**. (b) ODN-**5** • ODN-**6**. (c) ODN-**7** • ODN-**8**. (d) ODN-**10** • ODN-**14**. (e) ODN-**11** • ODN-**15**. (f) ODN-**12** • ODN-**16**. (g) ODN-**3** • ODN-**10**. (h) ODN-**7** • ODN-**12**.





Fig. 20A Thermal denaturation curves (heating and cooling) of ps and aps duplexes with increasing concentration of Ag^+ ions. The experiments were performed with 5 µM duplex concentration in 100 mM NaOAc, 10 mM Mg(OAc)₂ buffer (pH 7.5) at 260 nm. (a) ODN-**3** • ODN-**4**. (b) ODN-**5** • ODN-**6**. (c) ODN-**7** • ODN-**8**. (d) ODN-**10** • ODN-**14**. (e) ODN-**11** • ODN-**15**. (f) ODN-**12** • ODN-**16**. (g) ODN-**3** • ODN-**10**. (h) ODN-**7** • ODN-**12**.

References.

J. A. McDowell and D. H. Turner, *Biochemistry*, 1996, **35**, 14077–14089.
 (*a*) D. Goldman and T. I. Kalman, *Nucleosides Nucleotides*, 1983, **2**, 175-187; (*b*) K.
 Gislason and S. T. Sigurdsson, *Eur. J. Org. Chem.*, 2010, 4713-4718.
 A. T. R. Williams, S. A. Winfield and J. N. Miller, *Analyst*, 1983, **108**, 1067-1071.
 (*a*) H. Torigoe, Y. Miyakawa, A. Ono and T. Kozasa, *Nucleosides, Nucleotides Nucleic Acids*, 2011, **30**, 149-167; (*b*) H. Torigoe, I. Okamoto, T. Dairaku, Y. Tanaka, A. Ono and T. Kozasa, *Biochimie*, 2012, **94**, 2431-2440.



Fig. S21 ¹H NMR (300 MHz, DMSO- d_6) spectrum of compound **1**.



Fig. S22 13 C NMR (75 MHz, DMSO- d_6) spectrum of compound 1.





Fig. S24 1 H- 13 C gated-decoupled (75 MHz, DMSO- d_6) spectrum of compound **1**.



Fig. S25 ¹H NMR (300 MHz, DMSO- d_6) spectrum of compound **5**.



Fig. S26 13 C NMR (75 MHz, DMSO- d_6) spectrum of compound **5**.



Fig. S28 1 H- 13 C gated-decoupled (75 MHz, DMSO- d_6) spectrum of compound **5**.



Fig. S29 ¹H NMR (300 MHz, CDCl₃) spectrum of compound **6**.



Fig. S30³¹P NMR (121 MHz, CDCl₃) spectrum of compound **6**.



Fig. S31 ¹H NMR (300 MHz, DMSO- d_6) spectrum of compound **3**.



Fig. S32 13 C NMR (75 MHz, DMSO- d_6) spectrum of compound **3**.



Fig. S33 DEPT-135 (75 MHz, DMSO-*d*₆) spectrum of compound 3.



Fig. S34 1 H- 13 C gated-decoupled (75 MHz, DMSO- d_6) spectrum of compound **3**.



Fig. S35 ¹H NMR (300 MHz, DMSO- d_6) spectrum of compound **7**.



Fig. S36 13 C NMR (75 MHz, DMSO- d_6) spectrum of compound 7.



Fig. S38 1 H- 13 C gated-decoupled (75 MHz, DMSO- d_6) spectrum of compound **7**.



Fig. S39 ¹H NMR (300 MHz, CDCl₃) spectrum of compound 8.



Fig. S40 ³¹P NMR (121 MHz, CDCl₃) spectrum of compound 8.